P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

Схожі ресурси

• P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
  за авторством: Evangelos Terpos, та інші
  Опубліковано: (2023-08-01)
• Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
  за авторством: Evangelos Terpos, та інші
  Опубліковано: (2024-02-01)
• P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
  за авторством: I. Ntanasis-Stathopoulos, та інші
  Опубліковано: (2023-05-01)
• PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
  за авторством: Ioannis Ntanasis-Stathopoulos, та інші
  Опубліковано: (2023-08-01)
• B06 | BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE/DEXAMETHASONE IN NEWLY DIAGNOSED INTERMEDIATE-FIT AND FRAIL MULTIPLE MYELOMA: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 1/2 BELARD CLINICAL TRIAL
  за авторством: E. Terpos, та інші
  Опубліковано: (2026-04-01)